Results of Operations and Financial Condition. On November 3, 2026, First Tracks Biotherapeutics, Inc. (“First Tracks”) issued a press release announcing its financial results for the three and nine months ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities…

Entry into a Material Definitive Agreement. On October 19, 2026 (the “Closing Date”), First Tracks Biotherapeutics, Inc. (the “Company”) closed its previously announced private placement (the “Private Placement”) of an aggregate 6,106,870 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share. At the closing of the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the investors in the Private Placeme…

The Offered Securities to be issued in connection with the Purchase Agreement will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and will be issued in reliance on exemptions from registration requirements thereof, including exemptions provided by Section 4(a)(2) of the Securities Act. As of October 12, 2026, the Company had 35,909,814 shares of Common Stock issued and outstanding.

Entry into a Material Definitive Agreement. On October 15, 2026, First Tracks Biotherapeutics, Inc. (“First Tracks Biotherapeutics” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain third party investors (collectively, the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate 6,106,870 shares of the Company’s common stock (the “Common Stock”), par value $0.001 per share (the “Offered Securities”) to the Investors…

by reference. The information furnished in Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. Forw…

Results of Operations and Financial Condition. On August 12, 2026, First Tracks Biotherapeutics, Inc. (“First Tracks”) issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchang…

Entry into a Material Definitive Agreement. On June 15, 2026, First Tracks Biotherapeutics, Inc. (the “Company”), entered into a Sublease Agreement (the “Sublease”) with AnaptysBio, Inc., a Delaware corporation (“AnaptysBio”), pursuant to which AnaptysBio agreed to sublease to the Company approximately 45,057 rentable square feet of space located at 10770 Wateridge Circle, San Diego, California 92121 (the “Premises”). The Premises are currently leased by AnaptysBio from Wateridge Property Own…

Results of Operations and Financial Condition. On May 14, 2026, First Tracks Biotherapeutics, Inc. (“First Tracks”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1…

Changes in Control of Registrant. The information set forth under

In connection with and prior to the Spin-Off and Distribution, AnaptysBio transferred its First Tracks Biotherapeutics Business to the Company. The Company’s audited combined financial statements included in the Information Statement are incorporated by reference herein.

Entry into a Material Definitive Agreement. Prior to the Distribution Date, in connection with the Spin-Off, the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the “Spin Agreements”) with AnaptysBio that set forth the principal actions taken or to be taken in connection with the Spin-Off and that govern the relationship between us and AnaptysBio following the Spin-Off. Separation and Distribution Agreement We entered into a Sepa…

Other Events. On April 20, 2026, the Company issued a press release announcing the completion of the Spin-Off. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this

Chief Financial Officer — Ajim Tamboli: The company appointed Ajim Tamboli as the Chief Financial Officer, effective as of the Spin-Off.

Material Modification to Rights of Security Holders. The information set forth under

Unregistered Sales of Equity Securities. On the Distribution Date, in connection with the Spin-Off, the Company issued 29,100,802 shares of Common Stock to AnaptysBio in consideration for the transfer of certain entities that are part of AnaptysBio’s biopharma business. After this issuance, AnaptysBio held 29,100,902 shares of Common Stock. The shares of Common Stock issued to AnaptysBio were issued in reliance upon an exemption from registration pursuant to Section 4(a)(2) under the Securiti…

Regulation FD Disclosure. First Tracks Biotherapeutics, Inc. (the “Company”) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form 10, initially filed with the SEC on March 3, 2026 (as amended, the “Registration Statement”), relating to the distribution of all of the shares of the Company’s common stock by AnaptysBio, Inc. (“AnaptysBio”) to holders of AnaptysBio common stock on a pro rata basis (the “Spin-Off”). On April 1, 2026, the Re…